These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

906 related items for PubMed ID: 15824338

  • 1. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.
    Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Achiti I, Confavreux C, Coustans M, le Page E, Edan G, McDonnell GV, Hawkins S, Trojano M, Liguori M, Cocco E, Marrosu MG, Tesser F, Leone MA, Weber A, Zipp F, Miterski B, Epplen JT, Oturai A, Sørensen PS, Celius EG, Lara NT, Montalban X, Villoslada P, Silva AM, Marta M, Leite I, Dubois B, Rubio J, Butzkueven H, Kilpatrick T, Mycko MP, Selmaj KW, Rio ME, Sá M, Salemi G, Savettieri G, Hillert J, Compston DA.
    Neurology; 2005 Apr 12; 64(7):1144-51. PubMed ID: 15824338
    [Abstract] [Full Text] [Related]

  • 2. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score.
    Guerrero AL, Laherrán E, Gutiérrez F, Martín-Polo J, Iglesias F, Alcázar C, Peralta J, Rostami P.
    Acta Neurol Scand; 2008 Jan 12; 117(1):21-5. PubMed ID: 17883422
    [Abstract] [Full Text] [Related]

  • 3. The multiple sclerosis severity score (MSSS) predicts disease severity over time.
    Pachner AR, Steiner I.
    J Neurol Sci; 2009 Mar 15; 278(1-2):66-70. PubMed ID: 19138773
    [Abstract] [Full Text] [Related]

  • 4. Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis.
    Markianos M, Koutsis G, Evangelopoulos ME, Mandellos D, Karahalios G, Sfagos C.
    J Neurochem; 2009 Jan 15; 108(1):158-64. PubMed ID: 19014375
    [Abstract] [Full Text] [Related]

  • 5. Prognosis of the individual course of disease: the elements of time, heterogeneity and precision.
    Daumer M, Neuhaus A, Herbert J, Ebers G.
    J Neurol Sci; 2009 Dec 15; 287 Suppl 1():S50-5. PubMed ID: 20106349
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Costs and quality of life of multiple sclerosis in Austria.
    Kobelt G, Berg J, Lindgren P, Plesnilla C, Baumhackl U, Berger T, Kolleger H, Vass K.
    Eur J Health Econ; 2006 Sep 15; 7 Suppl 2():S14-23. PubMed ID: 17310339
    [Abstract] [Full Text] [Related]

  • 11. Change in disability profile and quality of life in multiple sclerosis patients: a five-year longitudinal study using the Multiple Sclerosis Impact Profile (MSIP).
    Wynia K, van Wijlen AT, Middel B, Reijneveld SA, Meilof JF.
    Mult Scler; 2012 May 15; 18(5):654-61. PubMed ID: 21965423
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test.
    Drake AS, Weinstock-Guttman B, Morrow SA, Hojnacki D, Munschauer FE, Benedict RH.
    Mult Scler; 2010 Feb 15; 16(2):228-37. PubMed ID: 20028710
    [Abstract] [Full Text] [Related]

  • 15. Cigarette smoking and progression in multiple sclerosis.
    Koch M, van Harten A, Uyttenboogaart M, De Keyser J.
    Neurology; 2007 Oct 09; 69(15):1515-20. PubMed ID: 17923613
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Costs and quality of life for patients with multiple sclerosis in Belgium.
    Kobelt G.
    Eur J Health Econ; 2006 Sep 09; 7 Suppl 2():S24-33. PubMed ID: 17318662
    [Abstract] [Full Text] [Related]

  • 18. Costs and quality of life of multiple sclerosis in Switzerland.
    Kobelt G, Berg J, Lindgren P, Gerfin A, Lutz J.
    Eur J Health Econ; 2006 Sep 09; 7 Suppl 2():S86-95. PubMed ID: 17310338
    [Abstract] [Full Text] [Related]

  • 19. Patient reported outcomes in benign multiple sclerosis.
    Hviid LE, Healy BC, Rintell DJ, Chitnis T, Weiner HL, Glanz BI.
    Mult Scler; 2011 Jul 09; 17(7):876-84. PubMed ID: 21372114
    [Abstract] [Full Text] [Related]

  • 20. Costs and quality of life of multiple sclerosis in Germany.
    Kobelt G, Berg J, Lindgren P, Elias WG, Flachenecker P, Freidel M, König N, Limmroth V, Straube E.
    Eur J Health Econ; 2006 Sep 09; 7 Suppl 2():S34-44. PubMed ID: 17310337
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.